scout
|Videos|November 8, 2017

Dr. Ledermann on the Results of the ARIEL3 Trial in Ovarian Cancer

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Results of ARIEL3 showed that there was a significant improvement in progression-free survival with maintenance rucaparib in the BRCA-mutant population, the homologous recombination deficient (HRD) cohort, and the all-comers cohort.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME